3.39
price down icon5.57%   -0.20
pre-market  Pre-market:  3.28   -0.11   -3.24%
loading
Xenetic Biosciences Inc stock is traded at $3.39, with a volume of 14,252. It is down -5.57% in the last 24 hours and down -19.19% over the past month. Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.
See More
Previous Close:
$3.59
Open:
$3.68
24h Volume:
14,252
Relative Volume:
1.68
Market Cap:
$5.23M
Revenue:
$2.54M
Net Income/Loss:
$-4.13M
P/E Ratio:
-1.2327
EPS:
-2.75
Net Cash Flow:
$-4.11M
1W Performance:
-10.55%
1M Performance:
-19.19%
6M Performance:
-15.05%
1Y Performance:
-18.71%
1-Day Range:
Value
$3.2501
$3.68
1-Week Range:
Value
$3.2501
$3.845
52-Week Range:
Value
$2.78
$5.20

Xenetic Biosciences Inc Stock (XBIO) Company Profile

Name
Name
Xenetic Biosciences Inc
Name
Phone
781-778-7720
Name
Address
945 CONCORD ST., FRAMINGHAM, MA
Name
Employee
4
Name
Twitter
@XeneticBio
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
XBIO's Discussions on Twitter

Compare XBIO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
XBIO
Xenetic Biosciences Inc
3.39 5.23M 2.54M -4.13M -4.11M -2.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
502.92 129.14B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
680.61 74.41B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
581.21 35.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
241.75 31.30B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
254.57 27.35B 3.32B -860.46M -1.04B -8.32

Xenetic Biosciences Inc Stock (XBIO) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-08-20 Initiated Maxim Group Buy

Xenetic Biosciences Inc Stock (XBIO) Latest News

pulisher
Mar 13, 2025

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses - ACCESS Newswire

Mar 13, 2025
pulisher
Mar 13, 2025

Breakthrough: New DNase I Treatment Supercharges CAR T Cell Cancer Therapy Success - StockTitan

Mar 13, 2025
pulisher
Mar 13, 2025

Xenetic Biosciences (XBIO) Expected to Announce Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 05, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Update - Defense World

Mar 05, 2025
pulisher
Mar 05, 2025

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment Conference - ACCESS Newswire

Mar 05, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Announces Reverse Stock Split of Common Stock - ACCESS Newswire

Mar 02, 2025
pulisher
Mar 02, 2025

Xenetic Biosciences, Inc. Announces Closing of $6.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - ACCESS Newswire

Mar 02, 2025
pulisher
Feb 27, 2025

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting - Milton Daily Standard

Feb 27, 2025
pulisher
Feb 27, 2025

Can Xenetic's DNase I Innovation Finally Crack the Solid Tumor Barrier for CAR-T Therapy? - StockTitan

Feb 27, 2025
pulisher
Feb 14, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 21.4% in January - Defense World

Feb 14, 2025
pulisher
Feb 07, 2025

Xenetic Biosciences, Inc. Presents at the H.C. Wainwright 26th Annual Global Investment Conference - ACCESS Newswire

Feb 07, 2025
pulisher
Jan 30, 2025

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Up 1,920.0% in January - Defense World

Jan 30, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. Announces Partner's Filing of Registration Dossier in Russia for Epolong Product Candidate That Utilizes Xenetic's PolyXen(R) Platform Technology - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 26, 2025

Xenetic Biosciences, Inc. Extends Research Agreement with the University of Virginia for the Advancement of its DNase-Based Oncology Platform - ACCESS Newswire

Jan 26, 2025
pulisher
Jan 25, 2025

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update - ACCESS Newswire

Jan 25, 2025
pulisher
Jan 22, 2025

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results - ACCESS Newswire

Jan 22, 2025
pulisher
Jan 21, 2025

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment - ACCESS Newswire

Jan 21, 2025
pulisher
Jan 16, 2025

XBIOW (Xenetic Biosciences) Operating Income : $-4.36 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 16, 2025
pulisher
Jan 13, 2025

XBIOW (Xenetic Biosciences) Dividend Yield % : 0.00% (As of Jan. 13, 2025) - GuruFocus.com

Jan 13, 2025
pulisher
Jan 11, 2025

XBIOW (Xenetic Biosciences) Cash Flow from Financing : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com

Jan 11, 2025
pulisher
Dec 27, 2024

Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Drops By 93.8% - Defense World

Dec 27, 2024
pulisher
Dec 17, 2024

Xenetic Biosciences Advances Revolutionary DNase Cancer Treatment Platform with UVA Partnership - StockTitan

Dec 17, 2024
pulisher
Dec 16, 2024

Xenetic Biosciences Extends Breakthrough Cancer Research Program with UVA Through 2025 - StockTitan

Dec 16, 2024
pulisher
Dec 13, 2024

Xenetic Biosciences shareholders elect directors, approve auditor By Investing.com - Investing.com UK

Dec 13, 2024
pulisher
Dec 06, 2024

Xenetic and PeriNess partner for cancer treatment trials By Investing.com - Investing.com Canada

Dec 06, 2024
pulisher
Dec 05, 2024

Xenetic and PeriNess partner for cancer treatment trials - Investing.com

Dec 05, 2024
pulisher
Dec 05, 2024

Xenetic Biosciences, Inc. Enters into Clinical Trial Services Agreement with PeriNess Ltd. to Accelerate Development of DNase I Oncology Program - AccessWire

Dec 05, 2024
pulisher
Dec 04, 2024

Xenetic Biosciences (STU:3XB0) Momentum Rank : 8 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024
pulisher
Nov 30, 2024

Xenetic Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 30, 2024
pulisher
Nov 29, 2024

Xenetic Biosciences Inc (NASDAQ:XBIO) Short Interest Down 43.2% in November - Defense World

Nov 29, 2024
pulisher
Nov 24, 2024

HC Wainwright Reiterates Neutral Rating for Xenetic Biosciences (NASDAQ:XBIO) - Defense World

Nov 24, 2024
pulisher
Nov 22, 2024

Xenetic Bio's DNase I Shows Breakthrough in Colorectal Cancer Treatment Efficacy | XBIO Stock News - StockTitan

Nov 22, 2024
pulisher
Nov 21, 2024

XBIOXenetic Biosciences, Inc. Latest Stock News & Market Updates - StockTitan

Nov 21, 2024
pulisher
Nov 21, 2024

Xenetic presents preclinical data on DNase I with CAR T cells in murine model - TipRanks

Nov 21, 2024
pulisher
Nov 21, 2024

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis - AccessWire

Nov 21, 2024
pulisher
Nov 21, 2024

Xenetic Bio's DNase I + CAR T Cell Therapy Shows Breakthrough in Melanoma Treatment | XBIO Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 15, 2024

Xenetic Biosciences Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance

Nov 15, 2024
pulisher
Nov 13, 2024

Xenetic reports Q3 EPS (28c) vs. (69c) last year - TipRanks

Nov 13, 2024
pulisher
Nov 13, 2024

Xenetic Bio Q3: R&D Costs Drop 64% as DNase Cancer Program Advances | $6.8M Cash | XBIO Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 13, 2024

Xenetic Biosciences: Q3 Earnings Snapshot - Houston Chronicle

Nov 13, 2024

Xenetic Biosciences Inc Stock (XBIO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$75.07
price up icon 1.39%
$305.39
price down icon 0.55%
$19.19
price down icon 3.62%
$32.68
price down icon 0.52%
$97.47
price down icon 2.84%
biotechnology ONC
$254.57
price up icon 1.89%
Cap:     |  Volume (24h):